Vor Biopharma Inc. 48-week Phase 3 Clinical Trial Data for Telitacicept in Primary Sjögren’s Disease

Vor Biopharma Inc. reported the results of a 48-week Phase 3 clinical trial for telitacicept in primary Sjögren’s disease. The trial, conducted in China, demonstrated statistically significant and clinically meaningful improvements in both physician-assessed and patient-reported outcomes. The primary endpoint was the change from baseline in the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) at 24 weeks, with secondary endpoints including changes in ESSDAI at 12 weeks and other measures such as the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), physician’s global assessment (PGA), patient’s global assessment (PaGA), and multidimensional fatigue inventory (MFI-20). The trial showed deep and sustained improvements in systemic activity, symptoms, and function, with a favorable safety profile. Telitacicept, a dual BAFF/APRIL inhibitor, has the potential to become a best-in-disease therapy for primary Sjögren’s disease, addressing a significant unmet medical need.